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The bioenergetics of somatic dedifferentiation into
induced pluripotent stem cells remains largely
unknown. Here, stemness factor-mediated nuclear
reprogramming reverted mitochondrial networks
into cristae-poor structures. Metabolomic footprint-
ing and fingerprinting distinguished derived pluripo-
tent progeny from parental fibroblasts according
to elevated glucose utilization and production of
glycolytic end products. Temporal sampling demon-
strated glycolytic gene potentiation prior to induction
of pluripotent markers. Functional metamorphosis
of somatic oxidative phosphorylation into acquired
pluripotent glycolytic metabolism conformed to an
embryonic-like archetype. Stimulation of glycolysis
promoted, while blockade of glycolytic enzyme
activity blunted, reprogramming efficiency. Metabo-
proteomics resolved upregulated glycolytic enzymes
and downregulated electron transport chain com-
plex I subunits underlying cell fate determination.
Thus, the energetic infrastructure of somatic cells
transitions into a required glycolytic metabotype to
fuel induction of pluripotency.
INTRODUCTION
Stemness transcription factors reprogram somatic cell fate to
achieve embryonic-like pluripotency, the hallmark of induced
pluripotent stem cells (iPSC) (Takahashi and Yamanaka, 2006;
Meissner et al., 2007; Nelson et al., 2010). Developmental
metabolic plasticity is associated with pluripotent stem cell
fate specification (Dzeja et al., 2011), yet themetabolic dynamics
that match the bioenergetic demand of nuclear reprogramming
have not been established.264 Cell Metabolism 14, 264–271, August 3, 2011 ª2011 Elsevier IncSomatic cells largely depend on mitochondrial oxidative
phosphorylation as the primary source of energy production
(DeBerardinis et al., 2008). In contrast, embryonic stem cells
(ESC) rely on glycolytic ATP generation regardless of oxygen
availability (Chung et al., 2007; Kondoh et al., 2007). The reliance
on glycolysis reflects a low copy number of mitochondrial DNA
(mtDNA) as well as low numbers of nascent mitochondria (St.
John et al., 2005; Cho et al., 2006). Differentiation increases
mtDNA abundance and promotes mitochondrial biogenesis to
form networks of elongated and cristae-rich mitochondria in
support of competent oxidative metabolism (Facucho-Oliveira
et al., 2007; Chung et al., 2008). Divergent energetic require-
ments of somatic versus pluripotent phenotypes implicate a dis-
tinguishing metabolic profile characterizing dedifferentiation.
We here demonstrate by high-resolution metabolomics that in
nuclear reprogramming energy metabolism of iPSC progeny is
transformed away from the parental source. Upregulated glyco-
lytic enzymes and downregulated electron transport chain
subunits enabled a metabolic switch converting somatic oxida-
tive metabolism into a glycolytic flux-dependent, mitochondria-
independent state underlying pluripotent induction.RESULTS
Transformed Mitochondrial Infrastructure and
Metabolomic Profile Define Nuclear Reprogramming
Reprogramming by four stemness transcription factors (4F) re-
structured mouse embryonic fibroblasts (MEF), characterized
by organized mitochondrial networks, to a primordial cytotype
featuring an increased nuclear-to-cytosol ratio with few perinu-
clear mitochondria (Figures 1A–1D). Mature tubular and
cristae-rich somatic mitochondria transitioned into immature
spherical and cristae-poor structures in 4F iPSC, indicative of
bioenergetic remodeling (Figures 1B and 1D). High-resolution
1H nuclear magnetic resonance spectroscopy (NMR) quantifica-
tion of 18 extracellular metabolites (Figure 1E and Figure S1)
decoded the metabolic consequences of dedifferentiation by
separating the 4F iPSC metabolomic footprint from the parental.
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Figure 1. Nuclear Reprogramming Trans-
forms Mitochondrial Structure Inducing
a Distinct Metabolomic Footprint
Nuclear reprogramming induced regression from
elongated and cristae-rich mitochondria (m) of
MEFs (A and B) to spherical and cristae-poor
remnant structures in four stemness factor-derived
iPSCs (4F iPSC) (C and D). Insets demonstrate
conversion of fibroblast monolayers (A) into
compact clusters (C), which stained for the pluri-
potency marker alkaline phosphatase (AP). 1H
NMR spectra of extracellular metabolites from 4F
iPSC: 1, isoleucine; 2, leucine; 3, valine; 4, threo-
nine; 5, lactate; 6, alanine; 7, acetate; 8, methio-
nine; 9, glutamate; 10, pyruvate; 11, succinate; 12,
glutamine; 13, lysine; 14, b-glucose; 15, a-glucose;
16, tyrosine; 17, histidine; and 18, phenylalanine
(E). Principal component analysis segregated 4F
iPSCmetabolomic phenotypes away from theMEF
profile with principal component 1 accounting for
88% and 2 for 8% of the total variance (F). The
loading plot assigned glucose and lactate as key
metabolites contributing to segregation (G).
Increased utilization of glucose and production of
glycolytic end products in excess of MEF (H and I)
were reproduced in independent iPSC lines (4F
iPS1 and 4F iPS2). Values are mean ± SEM, n = 6.
*p < 0.05 versus MEF. See also Figure S1.
Cell Metabolism
Metabolomic Switch in Nuclear ReprogrammingMEF landscape (Figure 1F). Accordingly, glucose and lactate
were identified as distinguishing metabolites (Figure 1G). Rates
of glucose utilization (2.3 ± 0.1 and 2.2 ± 0.1 nmol/mg protein/
hr) and lactate production (4.4 ± 0.1 and 4.8 ± 0.1 nmol/mg
protein/hr) were significantly elevated in two 4F iPSC lines (4F
iPS1 and 4F iPS2) compared to MEF (1.8 ± 0.1 and 3.1 ±
0.1 nmol/mg protein/hr, respectively, n = 6, p < 0.05; Figures
1H and 1I). Thus, nuclear reprogramming induces mitochondrial
regression and extracellular metabolome resetting.
Transition from Somatic Oxidative Metabolism to
Pluripotent Glycolysis Supports iPSC Derivation
Intracellular metabolite fingerprinting validated the glycolytic
capacity of 4F iPSC, segregating the acquired metabolomic
pattern away from parental MEF and toward the pluripotent
ESC standard (Figure 2A and Figure S1B). The resolved 18
intracellular metabolite panel distinguished iPSC based upon
acetate, lactate, fumarate, and taurine concentrations (Figure 2B
and Figure S1C). 4F iPSC accumulation of acetate was similar toCell Metabolism 14, 264–2ESC (31.6 ± 0.9, 32.5 ± 1.0, and 29.2 ± 0.7
pmol/mg protein, n = 3) and distinct from
MEF (21.3 ± 0.5 pmol/mg protein, n = 3
populations, p < 0.05, Figure 2C). Compa-
rably, lactate was equivalent in 4F iPSC
and ESC (127 ± 3, 152 ± 5, and 140 ±
10 pmol/mg protein, n = 3), yet sig-
nificantly different from MEF (95 ±
5 pmol/mg protein, n = 3, p < 0.05; Fig-
ure 2D). Lactate efflux (5.3 ± 0.3 and
5.8 ± 0.1 nmol/mg protein/hr) at a rate
double that of MEF (2.8 ± 0.2 nmol/mgprotein/hr, n = 6, p < 0.05; Figure 2E) indicated functional glycol-
ysis in 4F iPSC. Consistent with the lower efficiency of glycolytic
ATP production compared to oxidative phosphorylation, the
ADP/ATP ratio, an index of cellular energy turnover, was reduced
in 4F iPSC and ESC compared to MEF (0.046 ± 0.002, 0.052 ±
0.001, and 0.053 ± 0.001 versus 0.070 ± 0.001, respectively,
n = 3, p < 0.05, Figure 2F). Overall, oxygen consumption was
low in 4F iPSC and ESC, compared to MEF both at baseline
(0.51 ± 0.04, 0.42 ± 0.07, and 0.36 ± 0.02 versus 1.8 ±
0.13 nmol/106 cells/min, n = 3, p < 0.05, Figure 2G) and under
electron transport chain uncoupling (0.98 ± 0.10, 1.22 ± 0.09,
and 0.95 ± 0.13 versus 6.51 ± 1.05 nmol/106 cells/min, n = 3,
p < 0.05, Figure 2H). 4F iPSC preserved the ability to generate
mitochondrial membrane potential and demonstratedmitochon-
drial hyperpolarization (Figures S3A–S3C), indicative of reduced
ATP utilization.
Treatment of MEF undergoing reprogramming with 2-deoxy-
glucose (2DG), a general inhibitor of glycolysis, blunted induction
of the pluripotent marker alkaline phosphatase (AP) (Figure 2I),71, August 3, 2011 ª2011 Elsevier Inc. 265
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Figure 2. Induction of Pluripotency Requires Functional Glycolysis
1H NMR fingerprinting of intracellular metabolites segregated 4F iPSC away from MEF and toward ESC (A). The first principal component accounts for 67% and
the second for 25% of the total variance. Acetate, taurine, lactate, and fumarate were identified as differentiating metabolites (B). Intracellular concentrations of
glycolytic end products were distinct in 4F iPSC compared to MEF and were similar to ESC patterns (C and D). Nuclear reprogramming elevated lactate efflux
rates (E) and reduced energy turnover in 4F iPSC, similar to that of ESC (F). Compared to MEF, iPSC and ESC had reduced basal oxygen consumption (G) and
lower maximal uncoupled oxidative capacity (H). During reprogramming, the glycolytic inhibitor, 2-deoxyglucose (2DG), blunted induction of the pluripotency
marker alkaline phosphatase (I). Glycolytic inhibitors, 1.25 mM 2DG and 100 mM 3-bromopyruvic acid (BrPA) and alternatively a stimulator of oxidative pyruvate
disposal, 5 mM dichloroacetate (DCA), reduced reprogramming efficiency, assessed by SSEA1 FACS analysis (J), without altering the growth pattern of MEF (K).
Stimulation of glycolysis by elevating extracellular glucose promoted the number of cells achieving the reprogrammed state (L) without altering growth of the
parental population (M). Values are mean ± SEM, n = 3 except for lactate efflux, where n = 6. In (A)–(G), *p < 0.05 versus MEF and #p < 0.05 versus 4F iPSC. In (H),
*p < 0.05 versus 4F iPS and ESC. In (I)–(M), *p < 0.05 versus vehicle (Veh) and #p < 0.05 versus 1.25 mM glucose. See also Figure S2.
Cell Metabolism
Metabolomic Switch in Nuclear Reprogrammingimplicating a glycolytic requirement for iPSC generation. Beyond
2DG, the hexokinase 2 inhibitor 3-bromopyruvic acid (BrPA)
(Ko et al., 2001) and pyruvate dehydrogenase kinase inhibitor
dichloroacetate (DCA) (Stacpoole, 1989) reduced reprogram-
ming efficiency (0.9% ± 0.3% in 2DG, 19.8% ± 1.0% in
BrPA, 17.3% ± 1.5% in DCA versus 27.8% ± 3.1% SSEA1-
positive cells in vehicle, n = 3, p < 0.05, Figure 2J) without impair-
ing cell growth (Figure 2K). Extracellular metabolite profiles
of MEF treated with 2DG or BrPA were consistent with inhibition
of glycolysis and stimulation of oxidative metabolism, while
DCA treatment stimulated mitochondrial function and acceler-
ated consumption of oxidative substrates (Figures S2A–S2C).
Glucose supplementation stimulated glycolytic flux, reduced
mitochondrial function (Figures S2D–S2F), and increased266 Cell Metabolism 14, 264–271, August 3, 2011 ª2011 Elsevier IncSSEA1-positive cell density (0.5% ± 0.3%, 16.6% ± 5.3%,
27.8% ± 1.1%, and 17.1% ± 4.7% SSEA1-positive cells in 0,
5, 12.5, and 25 mM glucose, n = 3, p < 0.05). Conversely, few
MEFs underwent nuclear reprogramming in the absence of
glucose (Figures 2L and 2M). Transition from somatic oxidative
metabolism to pluripotent glycolysis thus contributes to nuclear
reprogramming efficiency.
Glycolytic Flux Fuels Pluripotent Induction
Mitochondrial membrane potential served as a surrogate of
metabolic transition during nuclear reprogramming. Prospective
live cell imaging distinguished ESC-like compact clusters
with high tetramethylrhodamine methyl ester (TMRM) fluores-
cence from transfected nonreprogrammed MEF with low.
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Figure 3. Glycolytic Engagement Mobilizes Pluripotent Gene Induction
Similar to ESC and distinct from MEF, live cell imaging of mitochondrial membrane potential identified nascent compact cell clusters with high TMRM fluo-
rescence within 5–7 days of nuclear reprogramming (A). Compared to the low TMRM fluorescence population, high-fluorescence cells had significantly elevated
glycolytic gene expression (Glut1, Hxk2, Pfkm, and Ldha) within 1 week of reprogramming, which by 2 weeks of reprogramming equaled ESC glycolytic gene
expression (B). Of note, at week 1 of reprogramming, pluripotent gene expression (Fgf4, Nanog,Oct4, and Sox2) remained low in high TMRM fluorescence cells,
similar to the starting MEF, with pluripotent gene induction apparent during the second week (C). Shaded region represents mean ± SEM for ESC gene
expression. Values are mean ± SEM, n = 3. *p < 0.05 versus low TMRM population. Nuclear reprogramming switches oxidative MEF into glycolytic iPSC (D). See
also Figure S3.
Cell Metabolism
Metabolomic Switch in Nuclear Reprogrammingmitochondrial membrane fluorescence (Figure 3A). FACS
sampling of high TMRM cells at days 7 and 14 selected an emer-
gent subpopulation within small cell clusters, consistent withCelmitochondrial membrane potential polarization during dediffer-
entiation (Figures S3A–S3D). At day 7, high TMRM cells had
significantly elevated glycolytic gene expression (Glut1, Hxk2,l Metabolism 14, 264–271, August 3, 2011 ª2011 Elsevier Inc. 267
Cell Metabolism
Metabolomic Switch in Nuclear ReprogrammingPfkm, and Ldha), which met that of ESC by 2 weeks of reprog-
ramming (Figure 3B). In contrast, at 1 week of reprogramming,
pluripotent gene expression (Fgf4, Nanog, Oct4, and Sox2)
remained low in high TMRM cells, similar to starting MEF, with
pluripotent gene induction apparent only after 2 weeks (Fig-
ure 3C). Metabolic reprogramming thus precedes pluripotent
gene expression during somatic cell dedifferentiation from an
oxidative to a glycolytic iPSC phenotype (Figure 3D).
Reprogramming-Induced Metabolic Remodeling
Independent of c-Myc Induction
As c-Myc gene targets control rates of glycolysis and mitochon-
drial biogenesis (Dang, 2007), a cell line was derived without
c-Myc (3F iPSC). Similar to 4F iPSC, NMR metabolomic foot-
printing and fingerprinting segregated 3F iPSC away from
parental MEF (Figures 4A and 4B), based upon greater intracel-
lular and extracellular accumulation of glycolytic end products,
acetate (intracellular, 30.4 ± 0.8 versus 21.3 ± 0.5 pmol/mg
protein; extracellular, 0.41 ± 0.03 versus 0.035 ± 0.001 nmol/mg
protein/hr, n = 3, p < 0.05, Figure 4C) and lactate (intracellular,
188 ± 11 versus 95 ± 5 pmol/mg protein; extracellular, 4.1 ± 0.1
versus 3.0 ± 0.1 nmol/mg protein/hr, n = 3, p < 0.05, Figure 4D).
Consistent with accelerated glycolysis, 3F iPSC displayed
reduced energy turnover compared to MEF (0.039 ± 0.005
versus 0.068 ± 0.006, n = 3, p < 0.05, Figure 4E). Both 3F and
4F iPSC demonstrated limited oxidative capacity and elevated
lactate production (Figure 4F). Thus, nuclear reprogramming-
inducedmetabolic remodeling is characteristic of the iPS pheno-
type, independent of c-Myc transduction.
iPS Metabotype Arises through Proteome Restructuring
Metaboproteome dissection delineated a transformed molecular
signature in iPSC, distinct from parental MEF yet synonymous to
the metabolic protein profile of ESC (Figures 4G–4J, Figure S4,
Table S1 and Table S2). A label-free, quantitative proteomics
approach revealed the identities of glycolytic enzymes consis-
tently upregulated in pluripotent cytotypes relative to MEF (Fig-
ure4GandFigureS4A), confirmed independentlyby2Dgel-based
analysis (Figure 4I). Concomitantly, 65% of detected complex 1
subunits were downregulated in iPSC extracts (Figure 4H and
Figure S4B, Table S1) as validated by 2D gel-based analysis (Fig-
ure 4J), underscoring departure from MEF patterns and acquisi-
tion of a glycolytic-dependent profile (Figure 4K). In addition,
reprogramming was associated with selective downregulation
of the reducing equivalent entry points (complex I and II) (Fig-
ure S4C, Table S1). Thus, the resolved iPSC metaboproteome
unmasks a bioenergetic switch in energy production infrastruc-
ture underlying metabolic remodeling in nuclear reprogramming.
DISCUSSION
Nuclear reprogramming sets in motion dedifferentiation pro-
cesses leading to acquisition of pluripotency. This study
resolved the metabolic attributes underpinning iPSC generation.
Metaboproteome restructuring was demonstrated to underlie
conversion from somatic oxidative bioenergetics to glycolysis
of pluripotent progeny. Promotion of a glycolytic flux-depen-
dent, mitochondria-independent metabotype fostered nuclear
reprogramming.268 Cell Metabolism 14, 264–271, August 3, 2011 ª2011 Elsevier IncRegression of the parental somatic network of abundant
tubular and cristae-rich mitochondria into sparse spherical and
cristae-poor structures characterized iPSC progeny. A mito-
chondria-poor capacity would enable iPSC to revert reactive
oxygen species-dependent telomere shortening associated
with cellular aging (Passos et al., 2007; Marion et al., 2009). In
fact, mitochondrial regression and reduction of mtDNA as a
result of nuclear reprogramming are consistent with the undevel-
oped mitochondrial morphology of ESC (Kondoh et al., 2007;
Armstrong et al., 2010; Prigione et al., 2010; Zeuschner et al.,
2010). Induced reduction in mitochondria number and maturity
suggests metamorphosis of the bioenergetic infrastructure
underlying dedifferentiation.
Metabolomic footprinting and fingerprinting indeed demon-
strated distinct features of iPSC metabolism. The key metabolic
rates contributing to the iPSC phenotype were consistent among
multiple clones, and included elevated utilization of glucose and
accumulation of intracellular and extracellular lactate (via lactate
dehydrogenase) and acetate (via acetyl-CoA synthase or ATP-
citrate lyase), suggesting that accelerated glycolysis results in
accumulation of metabolic byproducts within the cell, followed
by metabolite exportation. iPSC demonstrated diminished basal
oxygen consumption and uncoupled oxidative capacity, indi-
cating departure from oxidative metabolism. ESCs also rely on
glycolytic ATP generation (Cho et al., 2006; Facucho-Oliveira
et al., 2007), with pluripotency maintenance sustained under
hypoxic conditions (Ezashi et al., 2005). Acquisition of an embry-
onic-like metabolic state is concomitant with global transcrip-
tional and epigenetic reorganization that includes demethylation
and activation of the promoter region of pluripotency inductors
(Bock et al., 2011; Plath and Lowry, 2011). A glycolytic burst
could promote linkage of energy metabolism with nuclear re-
programming-induced epigenetic resetting (Huangfu et al.,
2008; Friis et al., 2009; Wellen et al., 2009; Teperino et al.,
2010), priming the cell for pluripotent induction. Indeed, expres-
sion of glycolytic genes preceded pluripotent gene expression,
implicating metabolic remodeling as a facilitator of nuclear
reprogramming.
Complete oxidation of glucose limits generation of substrates
for biosynthetic pathways. Transition to glycolytic metabolism
would fuel specific cellular processes, such as ATP consumption
in the cell nucleus, and provide the necessary balance between
ATP generation and production of metabolic precursors to meet
anabolic requirements of dedifferentiation and associated prolif-
eration (DeBerardinis et al., 2008; Chung et al., 2010). Strategies
that in part stimulate glycolysis, including induction of hypoxia or
inhibition of the p53 pathway, increase nuclear reprogramming
efficiency (Kruse and Gu, 2006; Krizhanovsky and Lowe, 2009;
Yoshida et al., 2009). Consistent with the ability of small mole-
cules with known metabolic targets to modulate the appearance
of pluripotent colonies (Zhu et al., 2010), here stimulation of
glycolytic flux potentiated reprogramming, whereas oxidative
metabolism promotion preserved the somatic cytotype.
c-Myc, through its regulation of both glycolysis and mitochon-
drial metabolism, is a key contributor to the metabolic Warburg
effect, reflecting the tendency of highly proliferative cell types
to convert glucose to lactate despite sufficient oxygen for mito-
chondrial oxidative metabolism (Dang, 2007). Here 3F iPSC dis-
played equivalent metabolic profiles to 4F iPSC counterparts,.
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Figure 4. Metabolic Reprogramming Is Independent of c-Myc Transduction and Supported by Glycolytic/Electron Transport Chain
Proteome Switch
1H NMR cellular metabolomic fingerprints (n = 6) of three stemness factor-induced iPSC (3F iPSC) segregated, away from the somatic, the acquired pattern (first
principal component accounts for 97% and second for 1% of total variance) (A). Glycolytic end products, acetate and lactate, were key metabolites responsible
for segregation (B). Intracellular content and efflux of acetate and lactate were significantly elevated in the 3F iPSC compared to MEF (C and D) and associated
with reduced energy turnover (n = 6) (E). Compared to MEF, 3F iPSC had lower maximal oxidative capacity and higher lactate production similar to that of ESC,
albeit not fully overlapping with 4F iPSC (n = 3) (F). Proteome-wide label-free quantification segregated iPSC away from MEF toward an ESC pattern based on
agglomerative clustering of z score transformed data (n = 4) due to predominant glycolytic enzyme upregulation (G). Electron transport chain complex I subunits
were predominantly downregulated in pluripotent cytotypes, which clustered away from MEF (H). 2D gel quantification and MS/MS identification (n = 3)
independently confirmed glycolytic upregulation (I) and complex I downregulation (J). iPSC proteomic upregulation was mapped across the glycolytic pathway
(K). Values are mean ± SEM. *p < 0.05 versus MEF. Proteins are abbreviated by Swiss-Prot gene name. See also Figure S4 and Table S1 and Table S2.
Cell Metabolism
Metabolomic Switch in Nuclear Reprogrammingverifying that nuclear reprogramming-inducedmetabolic remod-
eling did not require c-Myc transduction. Proteomic dissection
resolved a metabolic infrastructure that distinguished 3F andCel4F iPSC from fibroblasts. Specifically, reprogramming induced
reciprocal changes in glycolytic enzymes and electron transport
chain components, indicating amolecular substrate contributingl Metabolism 14, 264–271, August 3, 2011 ª2011 Elsevier Inc. 269
Cell Metabolism
Metabolomic Switch in Nuclear Reprogrammingto the switch from oxidative to glycolytic metabolism. The
observed decreased expression of complex I and II subunits
would uncouple oxidative metabolism and ATP generation,
favoring glycolytic-dependent ATP production.
In summary, dedifferentiation of parental somatic cells in-
duced mitochondrial regression, electron transport chain down-
regulation, and glycolysis enzyme upregulation, revealing a
pluripotent glycolytic signature with limited dependence on
mitochondrial metabolism. Induction of the glycolytic metabo-
type supports anabolic and catabolic requirements for bona
fide pluripotency to regulate cell fate.
EXPERIMENTAL PROCEDURES
Transduction
Mouse embryonic fibroblasts were transduced with in-house HIV-based viral
vectors encoding OCT3/4, SOX2, and KLF4 in the presence or absence of
c-MYC to produce iPSC clones that met pluripotent criteria including expres-
sion of stem cell markers, embryoid body differentiation, teratoma formation,
diploid aggregation, and contribution to organogenesis (Martinez-Fernandez
et al., 2009; Nelson et al., 2009a, 2009b). Alternatively, iPSCs were derived
with a viPS (Open Biosystems) kit. iPSCs and mouse ESCs (R1) were induced
andmaintained in DMEM supplemented with 15%FBS, 25mMglucose, 2mM
Glutamax (Invitrogen), and 1 mM sodium pyruvate. Reprogramming efficiency
was quantified using an alkaline phosphatase staining kit (Stemgent) or FACS
analysis of SSEA1 expression (Millipore) on a LSR II flow cytometer.
Ultrastructure
Mitochondrial density and morphology were evaluated in 1% glutaraldehyde
and 4% formaldehyde fixed cells and examined as ultramicrotome sections
on a JEOL 1200 EXII electron microscope (Perez-Terzic et al., 2007).
Metabolomic Footprinting and Fingerprinting
For footprinting of extracellular metabolites (see the Supplemental Experi-
mental Procedures), 540 ml of media collected following 24 hr of culture was
added to 60 ml of D2O (Sigma) containing 5 mM sodium 3-(trimethylsilyl)propi-
onate-2,2,3,3-d4 (TSP) (Sigma) for chemical shift reference and 81.84 mM
formate (Sigma) for peak quantification reference (Turner et al., 2008). For
intracellular metabolite fingerprinting, neutralized perchloric acid extracts
were concentrated with a SpeedVac and suspended in 600 ml of 100 mM
phosphate buffer (pH 7.0) in D2O (Sigma) containing 0.5 mM TSP (Beckonert
et al., 2007). Identities of 1H NMR spectra peaks obtained on a Bruker Ultra-
shield 700 MHz spectrometer with a zgpr water suppression presaturation
pulse were assigned by comparison to reference values for chemical shift
and multiplicity, and confirmed by comparison to spectra of pure compounds
in the Human Metabolome Database (Govindaraju et al., 2000; Wishart
et al., 2009).
Metabolites and Oxygen Consumption
Lactate efflux rate was assessed in extracellular media using a lactate assay
(SUNY). Nucleotide concentrations were determined in neutralized perchloric
acid extracts by high-performance liquid chromatography, using a 0.1 M
phosphate (pH 6.5), 0.01 M tetrabutylammoniumhydrogensulfate, and 40%
methanol elution buffer (Chung et al., 2007). Oxygen consumption was
assessed using an electrode system (Hansatech) on 5 million trypsinized cells
suspended in DMEM. Maximal rate of uncoupled oxygen consumption was
assessed by serial additions of 2,4-dinitrophenol (Sigma).
TMRM Fluorescence Sorting and Gene Expression
Mitochondrial membrane potential was assessed at day 4–14 of reprogram-
ming by incubating with 20 nM TMRM (Anaspec) for 30 min at 37C, and
imaged with a LSM 510 Axiovert laser confocal microscope. By 1 and 2 weeks
of reprogramming, single-cell suspensions were incubated in TMRM and
separated by a FACS Aria Cell Sorter. Gene expression was examined on an
Eco RT-PCR system (Illumina).270 Cell Metabolism 14, 264–271, August 3, 2011 ª2011 Elsevier IncProteomics
Protein extracts were resolved by 2D gel electrophoresis and 4%–15% SDS-
PAGE (100 and 30 mg, respectively) and silver stained (Zlatkovic-Lindor et al.,
2010). For comparative analysis, SDS-PAGE lanes were excised, destained,
and prepared for LC-MS/MS, as were protein species from 2D gels identified
as significantly altered by PDQuest analysis (Zlatkovic-Lindor et al., 2010).
Isolated tryptic peptides were analyzed and identified by LTQ-Orbitrap mass
spectrometry. Label-free quantitative comparison of SDS-PAGE protein and
peptide abundance was carried out on acquired MS spectra using Rosetta
Elucidator’s differential workflow, with annotation performed using Peptide-
Teller and ProteinTeller (Neubert et al., 2008; Lomenick et al., 2009). See the
Supplemental Experimental Procedures.Statistical Analysis
Data are presented as mean ± SEM. Metabolic footprinting and fingerprinting
were analyzed by principal component analysis using JMP. Student’s t test
was used to evaluate two group comparisons and ANOVA with a Bonferroni
post-hoc correction for three group comparisons. A value of p < 0.05 was
considered significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2011.06.011.ACKNOWLEDGMENTS
The authors thank Mayo Clinic Nuclear Magnetic Resonance Core and Flow
Cytometry/Optical Morphology Shared Resource for assistance. This work
was supported by the National Institutes of Health (R01HL083439,
T32HL007111, R01HL085208, R56AI074363), Canadian Institutes of Health
Research, Marriott Program, and Mayo Clinic.
Received: October 18, 2010
Revised: May 1, 2011
Accepted: June 9, 2011
Published: August 2, 2011REFERENCES
Armstrong, L., Tilgner, K., Saretzki, G., Atkinson, S.P., Stojkovic, M., Moreno,
R., Przyborski, S., and Lako, M. (2010). Human induced pluripotent stem cell
lines show similar stress defence mechanisms and mitochondrial regulation
to human embryonic stem cells. Stem Cells 28, 661–673.
Beckonert, O., Keun, H.C., Ebbels, T.M., Bundy, J., Holmes, E., Lindon, J.C.,
and Nicholson, J.K. (2007). Metabolic profiling, metabolomic and metabo-
nomic procedures for NMR spectroscopy of urine, plasma, serum and tissue
extracts. Nat. Protoc. 2, 2692–2703.
Bock, C., Kiskinis, E., Verstappen, G., Gu, H., Boulting, G., Smith, Z.D., Ziller,
M., Croft, G.F., Amoroso, M.W., Oakley, D.H., et al. (2011). Reference maps of
human ES and iPS cell variation enable high-throughput characterization of
pluripotent cell lines. Cell 144, 439–452.
Cho, Y.M., Kwon, S., Pak, Y.K., Seol, H.W., Choi, Y.M., Park do, J., Park, K.S.,
and Lee, H.K. (2006). Dynamic changes in mitochondrial biogenesis and anti-
oxidant enzymes during the spontaneous differentiation of human embryonic
stem cells. Biochem. Biophys. Res. Commun. 348, 1472–1478.
Chung, S., Dzeja, P.P., Faustino, R.S., Perez-Terzic, C., Behfar, A., and Terzic,
A. (2007). Mitochondrial oxidative metabolism is required for the cardiac
differentiation of stem cells. Nat. Clin. Pract. Cardiovasc. Med. 4 (Suppl 1 ),
S60–S67.
Chung, S., Dzeja, P.P., Faustino, R.S., and Terzic, A. (2008). Developmental
restructuring of the creatine kinase system integratesmitochondrial energetics
with stem cell cardiogenesis. Ann. N Y Acad. Sci. 1147, 254–263..
Cell Metabolism
Metabolomic Switch in Nuclear ReprogrammingChung, S., Arrell, D.K., Faustino, R.S., Terzic, A., and Dzeja, P.P. (2010).
Glycolytic network restructuring integral to the energetics of embryonic stem
cell cardiac differentiation. J. Mol. Cell. Cardiol. 48, 725–734.
Dang, C.V. (2007). The interplay between MYC and HIF in the Warburg effect.
Ernst Schering Found. Symp. Proc., 35–53.
DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008).
The biology of cancer: metabolic reprogramming fuels cell growth and prolif-
eration. Cell Metab. 7, 11–20.
Dzeja, P.P., Chung, S., Faustino, R.S., Behfar, A., and Terzic, A. (2011).
Developmental enhancement of adenylate kinase-AMPK metabolic signaling
axis supports stem cell cardiac differentiation. PLoS ONE 6, e19300.
10.1371/journal.pone.0019300.
Ezashi, T., Das, P., and Roberts, R.M. (2005). LowO2 tensions and the preven-
tion of differentiation of hES cells. Proc. Natl. Acad. Sci. USA 102, 4783–4788.
Facucho-Oliveira, J.M., Alderson, J., Spikings, E.C., Egginton, S., and St John,
J.C. (2007). Mitochondrial DNA replication during differentiation of murine
embryonic stem cells. J. Cell Sci. 120, 4025–4034.
Friis, R.M., Wu, B.P., Reinke, S.N., Hockman, D.J., Sykes, B.D., and Schultz,
M.C. (2009). A glycolytic burst drives glucose induction of global histone
acetylation by picNuA4 and SAGA. Nucleic Acids Res. 37, 3969–3980.
Govindaraju, V., Young, K., and Maudsley, A.A. (2000). Proton NMR chemical
shifts and coupling constants for brain metabolites. NMR Biomed. 13,
129–153.
Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A.E.,
and Melton, D.A. (2008). Induction of pluripotent stem cells by defined
factors is greatly improved by small-molecule compounds. Nat. Biotechnol.
26, 795–797.
Ko, Y.H., Pedersen, P.L., and Geschwind, J.F. (2001). Glucose catabolism in
the rabbit VX2 tumor model for liver cancer: characterization and targeting
hexokinase. Cancer Lett. 173, 83–91.
Kondoh, H., Lleonart, M.E., Nakashima, Y., Yokode, M., Tanaka, M., Bernard,
D., Gil, J., and Beach, D. (2007). A high glycolytic flux supports the proliferative
potential of murine embryonic stem cells. Antioxid. Redox Signal. 9, 293–299.
Krizhanovsky, V., and Lowe, S.W. (2009). Stem cells: the promises and perils of
p53. Nature 460, 1085–1086.
Kruse, J.P., and Gu,W. (2006). p53 aerobics: themajor tumor suppressor fuels
your workout. Cell Metab. 4, 1–3.
Lomenick, B., Hao, R., Jonai, N., Chin, R.M., Aghajan, M., Warburton, S.,
Wang, J., Wu, R.P., Gomez, F., Loo, J.A., et al. (2009). Target identification
using drug affinity responsive target stability (DARTS). Proc. Natl. Acad. Sci.
USA 106, 21984–21989.
Marion, R.M., Strati, K., Li, H., Tejera, A., Schoeftner, S., Ortega, S., Serrano,
M., and Blasco, M.A. (2009). Telomeres acquire embryonic stem cell charac-
teristics in induced pluripotent stem cells. Cell Stem Cell 4, 141–154.
Martinez-Fernandez, A., Nelson, T.J., Yamada, S., Reyes, S., Alekseev, A.E.,
Perez-Terzic, C., Ikeda, Y., and Terzic, A. (2009). iPS programmed without
c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ.
Res. 105, 648–656.
Meissner, A., Wernig, M., and Jaenisch, R. (2007). Direct reprogramming of
genetically unmodified fibroblasts into pluripotent stem cells. Nat. Biotechnol.
25, 1177–1181.
Nelson, T.J., Martinez-Fernandez, A., Yamada, S., Mael, A.A., Terzic, A., and
Ikeda, Y. (2009a). Induced pluripotent reprogramming from promiscuous
human stemness-related factors. Clin. Transl. Sci. 2, 118–126.CelNelson, T.J., Martinez-Fernandez, A., Yamada, S., Perez-Terzic, C., Ikeda, Y.,
and Terzic, A. (2009b). Repair of acute myocardial infarction by human stem-
ness factors induced pluripotent stem cells. Circulation 120, 408–416.
Nelson, T.J., Martinez-Fernandez, A., and Terzic, A. (2010). Induced pluripo-
tent stem cells: developmental biology to regenerative medicine. Nat. Rev.
Cardiol. 7, 700–710.
Neubert, H., Bonnert, T.P., Rumpel, K., Hunt, B.T., Henle, E.S., and James, I.T.
(2008). Label-free detection of differential protein expression by LC/MALDI
mass spectrometry. J. Proteome Res. 7, 2270–2279.
Passos, J.F., Saretzki, G., Ahmed, S., Nelson, G., Richter, T., Peters, H.,
Wappler, I., Birket, M.J., Harold, G., Schaeuble, K., et al. (2007).
Mitochondrial dysfunction accounts for the stochastic heterogeneity in telo-
mere-dependent senescence. PLoS Biol. 5, e110. 10.1371/journal.pbio.
0050110.
Perez-Terzic, C., Faustino, R.S., Boorsma, B.J., Arrell, D.K., Niederlander,
N.J., Behfar, A., and Terzic, A. (2007). Stem cells transform into a cardiac
phenotype with remodeling of the nuclear transport machinery. Nat. Clin.
Pract. Cardiovasc. Med. 4 (Suppl 1 ), S68–S76.
Plath, K., and Lowry, W.E. (2011). Progress in understanding reprogramming
to the induced pluripotent state. Nat. Rev. Genet. 12, 253–265.
Prigione, A., Fauler, B., Lurz, R., Lehrach, H., and Adjaye, J. (2010). The senes-
cence-related mitochondrial/oxidative stress pathway is repressed in human
induced pluripotent stem cells. Stem Cells 28, 721–733.
Stacpoole, P.W. (1989). The pharmacology of dichloroacetate. Metabolism 38,
1124–1144.
St. John, J.C., Ramalho-Santos, J., Gray, H.L., Petrosko, P., Rawe, V.Y.,
Navara, C.S., Simerly, C.R., and Schatten, G.P. (2005). The expression ofmito-
chondrial DNA transcription factors during early cardiomyocyte in vitro differ-
entiation from human embryonic stem cells. Cloning Stem Cells 7, 141–153.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells
from mouse embryonic and adult fibroblast cultures by defined factors. Cell
126, 663–676.
Teperino, R., Schoonjans, K., and Auwerx, J. (2010). Histone methyl transfer-
ases and demethylases; can they link metabolism and transcription? Cell
Metab. 12, 321–327.
Turner, W.S., Seagle, C., Galanko, J.A., Favorov, O., Prestwich, G.D.,
Macdonald, J.M., and Reid, L.M. (2008). Nuclear magnetic resonance meta-
bolomic footprinting of human hepatic stem cells and hepatoblasts cultured
in hyaluronan-matrix hydrogels. Stem Cells 26, 1547–1555.
Wellen, K.E., Hatzivassiliou, G., Sachdeva, U.M., Bui, T.V., Cross, J.R., and
Thompson, C.B. (2009). ATP-citrate lyase links cellular metabolism to histone
acetylation. Science 324, 1076–1080.
Wishart, D.S., Knox, C., Guo, A.C., Eisner, R., Young, N., Gautam, B., Hau,
D.D., Psychogios, N., Dong, E., Bouatra, S., et al. (2009). HMDB: a knowledge-
base for the human metabolome. Nucleic Acids Res. 37, D603–D610.
Yoshida, Y., Takahashi, K., Okita, K., Ichisaka, T., and Yamanaka, S. (2009).
Hypoxia enhances the generation of induced pluripotent stem cells. Cell
Stem Cell 5, 237–241.
Zeuschner, D., Mildner, K., Zaehres, H., and Scholer, H.R. (2010). Induced
pluripotent stem cells at nanoscale. Stem Cells Dev. 19, 615–620.
Zhu, S., Li, W., Zhou, H., Wei, W., Ambasudhan, R., Lin, T., Kim, J., Zhang, K.,
and Ding, S. (2010). Reprogramming of human primary somatic cells by OCT4
and chemical compounds. Cell Stem Cell 7, 651–655.
Zlatkovic-Lindor, J., Arrell, D.K., Yamada, S., Nelson, T.J., and Terzic, A.
(2010). ATP-sensitive K+ channel-deficient dilated cardiomyopathy proteome
remodeled by embryonic stem cell therapy. Stem Cells 28, 1355–1367.l Metabolism 14, 264–271, August 3, 2011 ª2011 Elsevier Inc. 271
